Neonatal Brain Oxygenation Study
BOX
Targeted Cerebral Saturations in Extremely Preterm Infants
1 other identifier
interventional
100
1 country
1
Brief Summary
Implementing target ranges for regional cerebral saturations in extremely preterm infants in the first week of life may improve neurodevelopmental outcomes at 22-26 months corrected age compared to those without targeted cerebral saturations (Csat) using near-infrared spectroscopy (NIRS). Infants will be randomized to a targeted cerebral saturation monitoring group with visible reading of Csat or to a control group with cerebral saturation monitoring, but with blinded Csat measures. Those in the targeted Csat group will follow a treatment guideline to maintain cerebral oxygenation in the target range. The primary outcome is neurodevelopmental outcome as determined by Bayley III cognitive scale score.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 15, 2020
CompletedFirst Posted
Study publicly available on registry
June 19, 2020
CompletedStudy Start
First participant enrolled
August 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedApril 18, 2024
April 1, 2024
4.4 years
June 15, 2020
April 16, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Neurodevelopmental outcome
Neurodevelopmental outcomes will be assessed using the cognitive component of the Bayley Scales of Infant Development-III at 22-26 months of age. Scores range from 55-145 with higher number representing a better neurodevelopmental outcome.
22-26 months of age
Secondary Outcomes (2)
Death
from birth until hospital discharge, an average of 3 months.
Retinopathy of prematurity
from birth until hospital discharge, an average of 3 months.
Other Outcomes (1)
Burden of Cerebral hypoxia or hyperoxia
From birth until first 7 days of life
Study Arms (2)
Targeted Csats
ACTIVE COMPARATORSubjects randomized to the targeted Csat arm will have NIRS monitoring of cerebral saturations (Csat) and will have algorithm-driven clinical interventions to maintain Csat within target range in the first week of life.
Non-targeted Csats
NO INTERVENTIONSubjects randomized to the non-targeted Csat arm will have NIRS (near-infrared spectroscopy) monitoring of Csats, but Csat values will be obscured and not available to providers. These subjects will not have any algorithm-driven clinical interventions for Csat.
Interventions
In order to maintain cerebral saturations within targeted range, subjects in the targeted Csat arm will undergo clinical interventions based on clinical algorithm. Interventions may include administration of inotropes, fluid resuscitation, transfusion of blood products, and/or adjustment to respiratory support.
Eligibility Criteria
You may qualify if:
- Very preterm infants with gestational age at least 23 weeks but less than 29 completed weeks
- Less than 6 hours of age
You may not qualify if:
- Skin integrity insufficient to allow placement of NIRS sensors
- Decision not to provide full intensive care support
- Congenital condition, other than premature birth, that adversely affects life expectancy or neurodevelopment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Lucile Packard Children's Hospital Stanford
Palo Alto, California, 94304, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Assessors of neurodevelopmental outcome are blinded to targeted vs non-targeted monitoring
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 15, 2020
First Posted
June 19, 2020
Study Start
August 10, 2021
Primary Completion
December 31, 2025
Study Completion
December 31, 2025
Last Updated
April 18, 2024
Record last verified: 2024-04